UBS Group AG Boosts Stock Holdings in iShares US Pharmaceuticals ETF (NYSEARCA:IHE)

UBS Group AG increased its stake in iShares US Pharmaceuticals ETF (NYSEARCA:IHE – Get Rating) by 95.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 27,229 shares of the company’s stock after buying an additional 13,300 shares during the period. UBS Group AG’s holdings in iShares US Pharmaceuticals ETF were worth $4,616,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in iShares US Pharmaceuticals ETF by 48.2% in the first quarter. JPMorgan Chase & Co. now owns 3,233 shares of the company’s stock worth $628,000 after acquiring an additional 1,051 shares during the period. Vontobel Holding Ltd. purchased a new position in shares of iShares US Pharmaceuticals ETF during the 1st quarter valued at about $340,000. Blair William & Co. IL purchased a new position in shares of iShares US Pharmaceuticals ETF during the 1st quarter valued at about $58,000. Centaurus Financial Inc. bought a new stake in iShares US Pharmaceuticals ETF in the 1st quarter worth approximately $237,000. Finally, Atria Wealth Solutions Inc. bought a new stake in iShares US Pharmaceuticals ETF in the 1st quarter worth approximately $545,000.

iShares US Pharmaceuticals ETF Price Performance

NYSEARCA IHE opened at $177.39 on Thursday. The business’s 50 day moving average price is $184.79 and its 200-day moving average price is $181.51. iShares US Pharmaceuticals ETF has a fifty-two week low of $166.99 and a fifty-two week high of $202.77.

iShares US Pharmaceuticals ETF Profile

(Get Rating)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.